Sector: health
Conviction from: NASDAQ
52-week range: 90.39212.75
A biopharmaceutical company developing and commercializing therapies for rare and serious diseases, including pulmonary and inflammatory conditions.
5 tracked filer(s) hold this · 0 opened, 4 added, 1 trimmed in 30-JUN-2026
Aggregate 13FScore 66 — mean of 5 scored holder(s) · buyers (new/add) avg 72. Higher = the smart money in this name has the better track record.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|
| Stanley Druckenmiller / Duquesne | 95 | Added +140% | 2,774,690 | $295,837 | 5.7% |
| Bridgewater | 56 | Added +54% | 455,392 | $48,553,895 | 0.2% |
| Paul Tudor Jones / Tudor | 63 | Added +1510% | 513,591 | $54,759,072 | 0.1% |
| Steve Cohen / Point72 | 76 | Added +1297% | 539,097 | $57,478,522 | 0.1% |
| Ancora | 40 | Trimmed -7% | 200 | $21,324 | 0.0% |
Beyond 13F — activists, insiders, politicians & research
1 disclosed trade(s) by 1 filer(s).
6 disclosed trade(s) by 1 filer(s).
| Trade date | Who | Type | Amount | |
|---|
| 2026-09-22 | Trump, Donald J President | BUY | $15,001 - $50,000 | PTR |
| 2026-08-22 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| 2026-07-01 | Trump, Donald J President | SELL | $1,001 - $15,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |
| 2026-05-14 | Trump, Donald J President | BUY | $1,001 - $15,000 | PTR |